A press release by Ken Research cited an article published by AJMC®’s sister site The Center for Biosimilars®, titled “As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say.” The article noted that by 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs.
A piece by TulsaPeople Magazine spotlighted an article published on AJMC.com, the website of AJMC®. The article, “Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality,” indicated that screening and treatments for breast, colon, prostate, and lung cancers saw significant declines in 2020 due to the coronavirus disease 2019 pandemic, with oncology care delivery still yet to fully rebound.